back-arrow-image Search Health Packages, Tests & More

HE4 With Roma Index Test

50+ booked in last 3 days

Overview

The risk of ovarian malignancy algorithm (ROMA) incorporates cancer antigen 125 (CA125), human epididymal protein 4 (HE4), and menopausal status to assign women that present with an adnexal mass into a high-risk or low-risk group for finding an ovarian malignancy. 

Human Epithelial 4 (HE4) is a protein that is produced by cells in the ovaries and the lining of the respiratory tract. It is often elevated in women with ovarian cancer and can be used as a biomarker for the disease. CA125 is another protein that is often elevated in women with ovarian cancer, but it can also be elevated in women with other conditions, such as endometriosis, uterine fibroids, and pelvic inflammatory disease.

The ROMA index is a mathematical formula that combines the levels of HE4 and CA125 in the blood to estimate the risk of ovarian cancer. The ROMA index takes into account the age of the woman and whether she has reached menopause.

Associated Tests:

Cancer marker profile-Ovarian-Comprehensive

Ovarian Marker Profile

 

Written by: Supriya Kulkarni, Lead-Content & Training

Read More

HE4 With Roma Index Test Price

Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the HE4 With Roma Index Test with a clear pricing structure.

The HE4 With Roma Index Test Price in Mumbai is ₹ 2,600 .

We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.

Frequently Asked Questions

To assess Risk for finding an ovarian malignancy during surgery in women who present with an adnexal mass.

Test is usful for risk assessment for finding an ovarian malignancy during surgery in women who present with an adnexal mass.

The risk of ovarian malignancy algorithm (ROMA) incorporates cancer antigen 125 (CA125), human epididymal protein 4 (HE4), and menopausal status to assign women that present with an adnexal mass into a high-risk or low-risk group for finding an ovarian malignancy. ROMA is indicated for women who meet the following criteria: older than age 18, presenting with an adnexal mass for which surgery is planned, and who have not yet been referred to an oncologist. ROMA must be interpreted in conjunction with clinical and radiological assessment.

  • HE4 with ROMA index is a blood test that is used to assess the risk of ovarian cancer in women with a pelvic mass or cyst.

HE4 with ROMA index Test is done for monitoring recurrence or progression disease in patient with epithelial ovarian cancer

The HE4 with ROMA index test measures two biomarkers in the blood: HE4 (human epididymis protein 4) and CA125 (cancer antigen 125) and calculates the HOMA index using a formula.

 

A ROMA index score of less than 11.4 is considered low risk for ovarian cancer, while a score of 11.4 or higher is considered high risk.

The test involves drawing a small amount of blood from a vein in your arm. A healthcare professional will clean the area with an antiseptic, wrap an elastic band around your upper arm to make the veins more visible, and insert a needle into a vein to collect the blood sample. You may feel a brief prick or stinging sensation when the needle is inserted, but the procedure is generally painless

No special preparation is required for the test. However, it is recommended that you consult with your healthcare provider before taking the test, as they may have specific instructions or recommendations based on your individual medical history and current health status.

The HE4 with ROMA index test is typically recommended for women who have a pelvic mass or cyst that has been detected through pelvic examination or ultrasound. The test is used to assess the likelihood that the mass or cyst is cancerous. The test is particularly useful for women who are at high risk of ovarian cancer, such as those with a family history of the disease, a personal history of breast or colon cancer, or certain genetic mutations that increase the risk of ovarian cancer.

 

Some of the blood tests that may be ordered along with HE4 with ROMA index test include:

  • CA-125: This blood test measures the level of a protein called CA-125 in the blood. Elevated levels of CA-125 can indicate the presence of ovarian cancer, although other conditions can also cause elevated levels.
  • AFP: This blood test measures the level of alpha-fetoprotein (AFP) in the blood. Elevated levels of AFP can indicate the presence of certain types of ovarian cancer, as well as other conditions such as liver disease and pregnancy.
  • Inhibin A and B: These blood tests measure the levels of inhibin A and B, two hormones produced by the ovaries. Elevated levels of inhibin A and B can indicate the presence of certain types of ovarian cancer.
  • Estradiol: This blood test measures the level of the hormone estradiol in the blood. Elevated levels of estradiol can indicate the presence of certain types of ovarian cancer, as well as other conditions such as menopause and hormonal imbalances.

 

  • HE4: Human Epididymis Protein 4
  • CA125: Cancer Antigen 125
  • HOMA: Homeostatic Model Assessment

 

full medical check up

Ratings & Reviews (0)

No reviews available

Why Metropolis?

Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.

We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.

lab image
170+ Advanced Labs
lab image
Trusted by Leading Doctors & Hospitals
lab images
Over 2000+ Scientific Officers
reports image
Proficiency Testing for Accurate Reports

Latest Blogs & News

View More
View all